Hints and tips:
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...To boost supplies of antimalarials, generics manufacturers Teva and Novartis’ Sandoz have pledged to donate millions of doses to US hospitals....
...Teva, Mylan and others in the lawsuits have denied wrongdoing....
...Idexx said in October that the animal health market had experienced a “V-shaped recovery”....
...The Big Three are on course to control 40 per cent of the votes in American corporations in a couple of decades....
...Pfizer, Biogen, Novartis, Amgen and Mylan have already launched other biosimilar drugs and are expected to bring additional products to market in the next two years, Moody’s noted....
...Large, venerable corporations can struggle to see what lies ahead for their industry. Consider Novartis....
...The lawsuit is a stark example of the use of non-competes by large corporations, even against low-level hourly wage workers....
...Working with Sandoz, the generics arm of Swiss drugmaker Novartis, he and his colleagues have, in just six months, helped to shift roughly 80 per cent of eligible patients in England to a “biosimilar” version...
...As the pace of discoveries has quickened in recent years, it has turned into a kind of rock festival for the pharmaceutical industry....
...The company had just completed its first big live demonstration for a pharmaceutical company....
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...Alternatively, a positive result might encourage unwanted bids from peers such as Novartis and Pfizer....
...Outside the pharmaceuticals industry, Gilead Sciences is best known as the company that sparked a national outcry over the soaring cost of drugs in the US....
...But with Mylan, the generic drugmaker, gearing up to launch a cheaper “biosimilar” version of the medicine, analysts have started to ask how long the blockbuster franchise will survive....
...Novartis, the Swiss healthcare company, has held talks in recent weeks to acquire US drugmaker Amneal Pharmaceuticals, in a deal that would strengthen its $10bn generic drug franchise after it reported its...
...Heather Bresch, chief executive of Mylan, says the tactics are exactly the same ones used to try to hinder the introduction of generic drugs in the 1980s....
...Mylan, one of the largest generic drugmakers, is publishing data from a large study of its biosimilar version of Roche’s Herceptin, a breast cancer drug with annual sales of $6.6bn....
..., Novartis and Sanofi — which filed a so-called amicus brief in support of the legal case....
...Since the start of last year, pharmaceuticals companies have agreed $462bn of mergers and acquisitions — greater than the gross domestic product of Austria....
...Novartis has won about 30 per cent of the market from Amgen with its version of Neupogen in Europe....
...He then went on to run Heinz’s European business until he joined Novartis as head of consumer health in 2007, rising to head of pharmaceutical operations....
...US healthcare and pharmaceutical companies such as Mylan and AbbVie are among the corporations that have acquired all or parts of European businesses in recent weeks to escape US taxes....
...US drugmaker Mylan launched a fresh $9bn bid for Sweden’s Meda and Zimmer agreed to acquire rival medical products maker Biomet for $13.4bn....
...The corporation tax rate been reduced sharply and the government has also introduced new incentives to encourage pharmaceutical research....
International Edition